In:
Blood Purification, S. Karger AG, Vol. 27, No. 3 ( 2009), p. 306-310
Abstract:
〈 i 〉 Background: 〈 /i 〉 Increased plasma total homocysteine (tHcy) is a risk factor for the development of atherosclerosis and thrombosis present in over 90% of patients with end-stage renal disease (ESRD). We hypothesized that 12 mg/kg intravenous mesna administered predialysis would cause a significant decrease in plasma tHcy compared to placebo. 〈 i 〉 Methods: 〈 /i 〉 Patients with ESRD were recruited for 1- and 4-week placebo-controlled, cross-over studies. Intravenous 12 mg/kg mesna or placebo was administered 3 times weekly predialysis. 〈 i 〉 Results: 〈 /i 〉 One week of 12 mg/kg intravenous mesna significantly decreased predialysis plasma tHcy by 12.8 ± 7.8% (placebo 23.4 ± 8.0 μmol/l vs. mesna 20.5 ± 7.6 μmol/l, p = 0.0044). Four weeks of treatment yielded no significant decline in predialysis plasma tHcy (placebo 18.3 ± 8.5 μmol/l vs. mesna 18.7 ± 6.3 μmol/l, p = 0.41). 〈 i 〉 Conclusions: 〈 /i 〉 Although 12 mg/kg mesna significantly enhances tHcy excretion, prolonged treatment causes no change in plasma tHcy.
Type of Medium:
Online Resource
ISSN:
0253-5068
,
1421-9735
Language:
English
Publisher:
S. Karger AG
Publication Date:
2009
detail.hit.zdb_id:
1482025-0
Bookmarklink